logo-loader
viewMylan Inc.

New York prosecutors launch Mylan Pharma EpiPen anti-trust probe

The New York attorney general has launched an anti-trust investigation into Mylan Pharmaceuticals over the sale of EpiPens to local school districts

HilaryClinton.jpg
Clinton: Critic who wants to review how US drugs are priced

The New York attorney general has launched an anti-trust investigation into Mylan Pharmaceuticals (NASDAQ:MYL) over the sale of EpiPens to local school districts.

Eric Schneiderman’s office said on Tuesday that a preliminary review showed that Mylan “may have inserted potentially anticompetitive terms into its EpiPen sales contracts with numerous local school systems”.

The company has faced criticism in recent weeks from members of Congress and Democratic presidential nominee Hillary Clinton over sharp price increases of the product that is used by sufferers of severe allergies to stave off anaphylactic shock. Read more.

Mylan shares closed up 1.1% at $40.40 on Tuesday.

Quick facts: Mylan Inc.

Price: 21.89 USD

NASDAQ:MYL
Market: NASDAQ
Market Cap: $11.29 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lithium Australia outlines 2020 strategy

Lithium Australia NL (ASX:LIT) managing director Adrian Griffin discusses the company's vision and plans for 2020 with Proactive's Benjamin Starr. The company has an integrated strategy aimed at servicing the lithium battery industry and this includes resources, technology, processing and...

16 hours, 7 minutes ago

2 min read